Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 08/31 10:00:35 pm
57.39 USD   +0.26%
01:06a BRISTOL-MYERS S : to Hold Investor Teleconference to Discuss ESMO 20..
08/27 BRISTOL MYERS S : Canada Pension Plan Investment Board buys $99,115,..
08/24 INVESTIGATION F : BMY) over Potential Wrongdoing Announced
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 07:01pm CEST
   By Peter Loftus 
   Of  
 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
01:06a BRISTOL-MYERS SQUIBB : to Hold Investor Teleconference to Discuss ESMO 2016 Cong..
08/27 BRISTOL MYERS SQUIBB : Canada Pension Plan Investment Board buys $99,115,984 sta..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "MUTAMYCIN" Filed
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "FER-IN-SOL" Filed
08/25 BRISTOL MYERS SQUIBB : New Findings from Bristol-Myers Squibb in the Area of Cyc..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "ENFAMIL FAMILY BEGINNINGS" Fil..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "MVOKIS" Filed by Bristol-Myers..
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "ENFAMIL AR" Filed
08/25 BRISTOL MYERS SQUIBB : Trademark Application for "TEMPRA" Filed by Bristol-Myers..
08/25 BRISTOL MYERS SQUIBB : An Application for the Trademark "TRI-VI-SOL" Has Been Fi..
More news
Sector news : Pharmaceuticals - NEC
12:44a SUMITOMO DAINIPPON PHARMA : Sunovion Pharma to buy Canada's Cynapsus for $624 mi..
08/31 U.S. sues to stop Deere from buying Precision Planting
08/31DJSHIRE : Files 8K - Other Events
08/31DJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
08/31DJASTRAZENECA : Agrees to Pay $5.5 Million to Settle Alleged Bribery Probe
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/31 Ipsen Needs Its Big Swing In Oncology To Connect
08/30 Revamping My Dividend Growth Portfolio
08/27 What One Hand Gives, The Other Takes Away
08/27 Using My SWAN Decision Tree To Rate DGI Stocks
08/26 A Merck Versus Bristol Showdown
Advertisement
Financials ($)
Sales 2016 18 890 M
EBIT 2016 4 944 M
Net income 2016 4 379 M
Debt 2016 1 249 M
Yield 2016 2,70%
P/E ratio 2016 22,19
P/E ratio 2017 19,16
EV / Sales 2016 5,14x
EV / Sales 2017 4,67x
Capitalization 95 891 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 68,8 $
Spread / Average Target 20%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-16.57%95 640
JOHNSON & JOHNSON16.18%326 855
ROCHE HOLDING LTD.-12.84%214 220
PFIZER INC.7.81%211 570
NOVARTIS AG-10.02%209 772
ASTRAZENECA PLC7.33%174 031
More Results